KPV — 5mg

Description

KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte stimulating hormone (α-MSH). It carries α-MSH’s anti-inflammatory activity through melanocortin receptor (particularly MC1R) agonism, which inhibits NF-κB — the master transcription factor driving inflammatory cytokine production in virtually all tissue types. Unlike full α-MSH, KPV’s small size allows it to penetrate cell membranes and reach intracellular targets directly, and its minimal immunogenicity makes it suitable for local and systemic use.

In the gut, KPV has demonstrated significant efficacy in inflammatory bowel disease (IBD) models — reducing mucosal inflammation, improving barrier integrity, and normalizing cytokine profiles in colitis. For women, gut health is hormonally modulated: estrogen supports gut barrier integrity; progesterone can slow motility; the hormonal fluctuations of the menstrual cycle and perimenopause contribute to IBS and IBD flares. KPV provides direct mucosal anti-inflammatory activity at the site of inflammation. In skin, topical or injectable KPV reduces inflammatory conditions including psoriasis, rosacea, and acne — making it relevant for the cyclical skin inflammation that many women experience hormonally.

Female-calibrated dosing: For gut: 250–500mcg orally (dissolved in water) 2x/day, or subcutaneously. For skin: topical at 1–2% concentration, or 250mcg subcutaneously near affected area. Cycle 4–8 weeks.

Storage: Store lyophilized powder below -20°C. After reconstitution, refrigerate at 2–8°C and use within 30 days.